TIXiMED
Clinical-stage pharmaceutical company developing innovative oral therapies for diabetes and metabolic disorders.
About
Technology stack
detected 2026-06-18No comments yet. Be the first to share your take.
What does TIXiMED do?
TIXiMED is developing TIX100, a first-of-its-kind oral therapeutic that inhibits TXNIP, as a treatment for Type 1 and Type 2 Diabetes, as well as metabolic dysfunction, associated steatotic liver disease (MASLD). The company has successfully completed a Phase 1 clinical study of TIX100 in human subjects. TIX100 is an orally administered novel chemical entity that has shown efficacy in preclinical models and aims to address the underlying causes of diabetes without causing hypoglycemia or weight…
How much funding has TIXiMED raised?
TIXiMED has raised a total of $5M in funding. The most recent round on record is Seed.
Where is TIXiMED headquartered?
TIXiMED is headquartered in Birmingham, Alabama, United States.
When was TIXiMED founded?
TIXiMED was founded in 2021.
What industry does TIXiMED operate in?
TIXiMED operates in Biotechnology, Pharmaceuticals, HealthTech, Medical Devices, Healthcare.
How many employees does TIXiMED have?
TIXiMED has approximately 5 people on record.